Oncobiologics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Oncobiologics and buy or sell other stocks, ETFs, and their options commission-free!About ONS
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.
CEORobert Charles Jahr, MBA
CEORobert Charles Jahr, MBA
Employees—
Employees—
HeadquartersIselin, New Jersey
HeadquartersIselin, New Jersey
Founded2010
Founded2010
Employees—
Employees—
ONS Key Statistics
Market cap32.73M
Market cap32.73M
Price-Earnings ratio-0.36
Price-Earnings ratio-0.36
Dividend yield—
Dividend yield—
Average volume1.06M
Average volume1.06M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$3.39
52 Week high$3.39
52 Week low$0.3801
52 Week low$0.3801
Stock Snapshot
The current Oncobiologics(ONS) stock price is $0.79, with a market capitalization of 32.73M. The stock trades at a price-to-earnings (P/E) ratio of -0.36.
During the trading day, Oncobiologics(ONS) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Oncobiologics(ONS) stock has reached 0, versus its average volume of 1.06M.
The stock's 52-week range extends from a low of $0.38 to a high of $3.39.
The stock's 52-week range extends from a low of $0.38 to a high of $3.39.